ArticleClinical Medicine Insights. Oncology2012
Review of the treatment of non-small cell lung cancer with gefitinib.
Article in Clinical Medicine Insights. Oncology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 21 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 1 synthesis or guideline pooled it, 50 citations in OpenAlex.
- Impact of Precision Medicine in Diverse Cancers: A Meta-Analysis of Phase II Clinical Trials.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2015Pooled it
- Structure-Based Design, Synthesis, and Biological Evaluation of Oxadiazole-Morpholine Hybrids as Potent PARP-1 Inhibitors Inducing Apoptosis in Breast Cancer Cells.Drug development research · 2026Article
- DR.DEGMON: self-explainable deep neural network for drug-induced cell viability prediction incorporating differentially expressed genes and gene ontology.BMC medical genomics · 2026Article
- From Gefitinib to Amivantamab: Progress and Perspectives of Therapies Targeting the Epidermal Growth Factor Receptor in the Era of Precision Oncology.Journal of cancer prevention · 2026Review
- Research progress of small molecule targeted drugs for non-small cell lung cancer.Frontiers in oncology · 2026Review
- Unveiling the Potential of Nanosuspension Formulation Strategy for Improved Oral Bioavailability of Gefitinib.AAPS PharmSciTech · 2025Article
- Glycaemic abnormalities induced by small molecule tryosine kinase inhibitors: a review.Frontiers in pharmacology · 2024Review
- Measuring Drug Response with Single-Cell Growth Rate Quantification.Analytical chemistry · 2023Article
- LLPS of SQSTM1/p62 and NBR1 as outcomes of lysosomal stress response limits cancer cell metastasis.Proceedings of the National Academy of Sciences of the United States of America · 2023Article
- [Cigarette Smoke Induces Gefitinib Resistance in NSCLC Cells via ROS/Sirt3/SOD2 Pathway].Zhongguo fei ai za zhi = Chinese journal of lung cancer · 2023Article
- Busting the Breast Cancer with AstraZeneca's Gefitinib.Advances in pharmacological and pharmaceutical sciences · 2023Review
- Gefitinib initiates sterile inflammation by promoting IL-1β and HMGB1 release via two distinct mechanisms.Cell death & disease · 2021Article
- A comprehensive review of protein kinase inhibitors for cancer therapy.Expert review of anticancer therapy · 2018Review
- Structural Basis for the Inhibition of Cyclin G-Associated Kinase by Gefitinib.ChemistryOpen · 2018Article
- The lncRNA RHPN1-AS1 downregulation promotes gefitinib resistance by targeting miR-299-3p/TNFSF12 pathway in NSCLC.Cell cycle (Georgetown, Tex.) · 2018Article
- Cutaneous Side Effects and Transepidermal Water Loss To Gefitinib: A Study of 11 Patients.Dermatology and therapy · 2017Article
- Biopsy testing in an inoperable, non-small cell lung cancer population-a retrospective, real-life study in Sweden.Journal of thoracic disease · 2015Article
- [Relationship between EGFR Promoter Region Methylation and Secondary Resistance Which may be Induced by Gefitinib].Zhongguo fei ai za zhi = Chinese journal of lung cancer · 2015Article
- Inhibition of non-small cell lung cancer (NSCLC) growth by a novel small molecular inhibitor of EGFR.Oncotarget · 2015Article
- Critical appraisal of the role of gefitinib in the management of locally advanced or metastatic non-small cell lung cancer.OncoTargets and therapy · 2014Review
Corrections and comments
- Erratum issued
Authors and funding
8 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In the past decade, molecular-targeted drugs have been focused upon for the treatment of cancer. In 2002, gefitinib, an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor became available in Japan for the treatment of non-small cell lung cancer (NSCLC). Over 80% of selected patients, such as EGFR mutation-positive patients, respond to gefitinib treatment; however, most patients develop acquired resistance to gefitinib within a few years. Recently, many studies have been performed to determine precisely how to select patients who will respond to gefitinib, the best timing for its administration, and how to avoid the development of acquired resistance as well as adverse drug effects. This article reviews the use of gefitinib for the treatment of NSCLC from a pharmaceutical viewpoint.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.